Press Releases

  • Jan. 20, 2022 Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending November 30, 2021

    NEW HAVEN, Conn., Jan. 20, 2022 (GLOBE NEWSWIRE) — Bioasis Technologies Inc.?(TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers… Read more »

  • Dec. 16, 2021 Bioasis Announces Annual General Meeting Results

    NEW HAVEN, Conn., Dec. 16, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain… Read more »

  • Dec. 9, 2021 Bioasis to Attend and Present at Upcoming Industry Conferences

    NEW HAVEN, Conn., Dec. 09, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain… Read more »

  • Nov. 29, 2021 Bioasis Announces Annual General Meeting Details

    NEW HAVEN, Conn., Nov. 29, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain… Read more »

  • Oct. 28, 2021 Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2021

    NEW HAVEN, Conn., Oct. 28, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need,… Read more »

  • Sep. 30, 2021 Bioasis to Attend Upcoming Industry Conferences

    NEW HAVEN, Conn., Sept. 30, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain… Read more »

  • Aug. 18, 2021 Bioasis Technologies Inc. Announces the Appointment of Shadow Lake Group as Business Development Advisor

    NEW HAVEN, Conn., Aug. 18, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need,… Read more »

  • Aug. 9, 2021 Bioasis Announces Allowance of Japanese Patent Application in Japan Relating to xB³™ Fusion Protein Comprising Iduronate-2-sulfatase

    NEW HAVEN, Conn., Aug. 09, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology to enhance the delivery of biologics across the blood-brain barrier (“BBB”) for the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical… Read more »

  • Jul. 29, 2021 Bioasis Announces Filing of Its First Quarter Financial Statements and MD&A

    NEW HAVEN, Conn., July 29, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies Inc.?(TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”),?a?pre-clinical, research-stage?biopharmaceutical company developing its proprietary?xB3TM?platform?technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases,?today announced… Read more »

  • Jul. 20, 2021 Bioasis Technologies Inc. Announces Stock Option Grants, Jeffrey Sprouse Appointed Preclinical Program Manager

    NEW HAVEN, Conn., July 20, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need,… Read more »